Introduction
============

The retinoblastoma tumor suppressor (pRb) is lost by mutation or functional inactivation in virtually all human cancer ([@bib7]; [@bib5]). Its disruption leads to ectopic cell proliferation, apoptotic cell death, and incomplete differentiation and may cause cancer in many cell types ([@bib57]; [@bib9]; [@bib30]; [@bib23]). Rb exerts these effects by modulating the activity of transcription factors such as activating E2Fs ([@bib10]). These E2Fs activate cell cycle progression and DNA synthesis genes as well as proapoptotic, BH3-only factors that induce mitochondrial outer membrane permeabilization (MOMP) and trigger the intrinsic apoptotic machinery ([@bib15]; [@bib16]; [@bib17], [@bib18]). Activating E2Fs also induce p53 via ARF and MDM2, various apoptogenic factors, and autophagic genes ([@bib36]; [@bib49]; [@bib41]). pRb is also thought to stimulate lineage-specific transcription factors, including MyoD, myogenin, and MEF2C ([@bib14]; [@bib44]; [@bib38]), and sequester inhibitors of differentiation such as Id2, HDAC1, EID-1, and RBP2 ([@bib24]; [@bib28]; [@bib42]; [@bib4]). However, given that ectopic proliferation and apoptosis precludes differentiation, the exact role for pRb in differentiation remains ill defined. In this study, we addressed the function of Rb during myogenesis by uncoupling its effect on cell survival or proliferation from its effect on differentiation.

Results and discussion
======================

Rb deficiency during myogenic differentiation induces autophagy
---------------------------------------------------------------

To identify cell-autonomous functions of pRb during skeletal myogenesis, we analyzed the differentiation of primary Rb^−/−^ myoblasts isolated from limb muscles of embryonic day (E) 16.5 mini-Rb gene (mgRb):Rb^−/−^ fetuses. These mutant embryos harbor an mgRb that directs Rb expression to the placenta and nervous system but not muscles, thereby extending the life span of Rb^−/−^ embryos, which otherwise die at E13.5--14.5, to birth ([@bib57]; [@bib22]; unpublished data). In mgRb:Rb^−/−^ fetuses, myotubes are initially formed at E14.5--15.5 and express early muscle--specific markers, but they continue to synthesize DNA, fail to express late markers, and degenerate ([@bib57]; [@bib21]). As expected, primary myoblasts derived from mgRb:Rb^−/−^ muscles were devoid of pRb ([Fig. 1 A](#fig1){ref-type="fig"}).

![**Rb^−/−^ myoblasts transiently differentiate to form short myotubes that do not twitch, express autophagy markers, and slowly degenerate.** (A) Western blot analysis for pRb in DM-2 cultures. (B) Immunostaining for MHC in DM-3 and DM-6 differentiating myotubes. Nuclei were stained with DAPI (blue). (C) Mean number of myotubes on the indicated days after differentiation. Each time point is mean ± SD of six fields from six independent experiments. (D) TUNEL staining. Arrowheads indicate TUNEL-positive nuclei (green). (E) LC3-RFP expression in control (ctrl) and Rb^−/−^ myotubes. Insets show nuclear DAPI stain (blue). (F) Representative Western blot (*n* = 3) for LC3. Chloroquine was added 12 h before cell harvest. (G) Representative Western blot for LC3 in E16.5 control and mgRb:Rb^−/−^ muscles. (H) Quantification of LC3-II/tubulin ratio in E16.5 mgRb:Rb^−/−^ skeletal muscles relative to control as depicted in G (mean ± SD; *n* = 3). \*, P = 0.016 by Student's *t* test. (I) Representative Western blot for LC3-I and LC3-II expression in whole cell lysates from the indicated myotubes transduced with Ad.GFP or Ad.RbΔK11. (J) Quantification of LC3-II/tubulin ratio by Western blots as shown in I. Data represent mean ± SD (*n* = 7). \*, P = 0.047; \*\*, P = 0.005 by analysis of variance.](JCB_201005067_RGB_Fig1){#fig1}

When confluent cultures of control primary myoblasts were incubated in differentiation medium (DM), they spontaneously fused to form long multinucleated myotubes that started to twitch by day 3--4 and persisted for weeks in culture. Primary Rb^−/−^ myoblasts also fused to form short myotubes that contained three to six nuclei and expressed near-normal levels of myosin heavy chain (MHC; [Fig. 1 B](#fig1){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1)). However, at day 3 after differentiation (DM-3), these short myotubes degenerated; by day 6, virtually all had collapsed ([Fig. 1, B and C](#fig1){ref-type="fig"}; and Fig. S1 A). Thus, Rb^−/−^ myoblasts underwent abortive differentiation in vitro that recapitulated the muscle defects seen in mgRb:Rb^−/−^ embryos ([@bib57]; [@bib21]).

Cleaved (activated) caspase-3 and cleaved poly(ADP-ribose) polymerase, markers of intrinsic apoptosis, were elevated in differentiating Rb^−/−^ cultures relative to control (Fig. S1 B). However, TUNEL-positive nuclei were only detected in unfused myoblasts but not within myotubes at DM-2 and DM-3 ([Fig. 1 D](#fig1){ref-type="fig"}), indicating that myotube degeneration was not mediated by bona fide apoptotic cell death. Therefore, we asked whether degeneration of Rb^−/−^ myotubes was accompanied by autophagy, which, depending on the context, can lead to cell death or survival ([@bib35]). During autophagy, bulk cytoplasm, including whole organelles, is sequestered in vesicles termed autophagosomes that fuse to lysosomes (forming autolysosomes) for degradation ([@bib26]; [@bib37]; [@bib32]; [@bib48]; [@bib34]). To detect autophagy, myoblasts were transduced with an adenoviral vector expressing microtubule-associated protein 1A/1B light chain 3 (LC3) fused to red fluorescent protein (Ad.LC3-RFP; [@bib2]). LC3 accumulates on autophagosomes as a phosphatidylethanolamine (PE)-conjugated form (LC3-II; [@bib33]). In control myotubes, LC3 exhibited a diffuse red fluorescent pattern ([Fig. 1 E](#fig1){ref-type="fig"}, left). In contrast, in Rb^−/−^ myotubes, it was detected in perinuclear aggregates ([Fig. 1 E](#fig1){ref-type="fig"}, right), indicating autophagosome accumulation.

Autophagosome-bound LC3-II migrates faster than unconjugated LC3-I through denaturing protein gels ([@bib33]). At DM-2, LC3-II level was more than twofold higher in Rb^−/−^ myotube cultures relative to control (*n* = 3; [Fig. 1 F](#fig1){ref-type="fig"}). Chloroquine, an inhibitor of autophagosome--lysosome fusion, enhanced the level of LC3-II in both Rb^−/−^ and control cultures, demonstrating active autophagic flux. We also detected a 1.5 ± 0.12-fold (P = 0.016) increase in LC3-II expression in E16.5 mgRb:Rb^−/−^ limb muscle (*n* = 3) relative to control littermates (*n* = 3; [Fig. 1, G and H](#fig1){ref-type="fig"}). As control, transduction of a constitutively active, phosphomutant pRb (Ad.Rb^ΔK11^; [@bib20]) prevented collapse of Rb^−/−^ myotubes (not depicted) and, concomitantly, the accumulation of LC3-II by ∼1.8-fold (*n* = 7; P = 0.005; [Fig. 1, I and J](#fig1){ref-type="fig"}).

Rb deficiency during myogenic differentiation induces mitochondrial loss via autophagy
--------------------------------------------------------------------------------------

To detect mitochondria, we used MitoTracker, a live cell probe that accumulates in mitochondria with intact membrane potential. In control myotubes, MitoTracker revealed a uniform, netlike distribution of mitochondria throughout the cytoplasm ([Fig. 2 A](#fig2){ref-type="fig"}, top left). In contrast, at DM-2, Rb^−/−^ myotubes exhibited strong perinuclear MitoTracker-positive aggregates and relatively sparse cytosolic staining ([Fig. 2 A](#fig2){ref-type="fig"}, bottom left). On average, ∼70% of Rb^−/−^ myotubes contained perinuclear aggregates compared with \<10% control myotubes (P \< 0.001; [Fig. 2 B](#fig2){ref-type="fig"}). Cytochrome *c* also exhibited differential staining: it exhibited uniform distribution throughout control myotubes but irregular punctate/perinuclear staining in Rb^−/−^ myotubes (Fig. S1 C). To determine whether mitochondria accumulated within autophagosomes in Rb^−/−^ myotubes, we performed double staining with MitoTracker and LC3 antibody in the presence of chloroquine. Control myotubes contained very few cytoplasmic aggregates that stained positive for both MitoTracker and LC3 ([Fig. 2 C](#fig2){ref-type="fig"}, left). In contrast, 70% of Rb^−/−^ myotubes contained large perinuclear aggregates that stained positive for both markers ([Fig. 2 C](#fig2){ref-type="fig"}, middle). The level of overlap between LC3 and MitoTracker was 3.4-fold higher in the entire myotube population and fivefold higher in the 70% fraction of Rb^−/−^ myotubes that exhibited perinuclear mitochondrial aggregation ([Fig. 2 D](#fig2){ref-type="fig"}). EM analysis revealed overall reduced mitochondrial content and 2.2-fold increase in perinuclear accumulation of mitochondria in the entire Rb^−/−^ myotube population relative to control ([Fig. 2 E](#fig2){ref-type="fig"}). Some whole or partially degraded mitochondria engulfed by membrane, representing autophagosomes and autolysosomes ([@bib34]), were observed around nuclei ([Fig. 2 E](#fig2){ref-type="fig"}, asterisk) and in cytosol (Fig. S1 D). Consistent with these results, there was a 20% reduction in mitochondrial to nuclear DNA ratio, as determined by real-time PCR ([@bib1]), in Rb^−/−^ versus control cultures at DM-2 (P \< 0.001; [Fig. 2 F](#fig2){ref-type="fig"}) and a 50% reduction in E16.5 limb muscle (P = 0.009; [Fig. 2 G](#fig2){ref-type="fig"}). Moreover, there was a 20% decrease in ATP level in Rb^−/−^ myotube cultures (not depicted) and a 3.2-fold reduction in ATP level in E16.5 limb muscle relative to control (*n* = 3, P = 0.011; [Fig. 2 H](#fig2){ref-type="fig"}). The observed difference between the in vitro and in vivo results likely reflects the fact that in vitro cultures contain a smaller ratio of myotubes/unfused cells than skeletal muscle.

![**The Rb^−/−^ muscle defect is characterized by perinuclear mitochondrial/autophagosome aggregates, reduced mitochondrial DNA content, and reduced ATP production.** (A, left) MitoTracker staining. (right) MitoTracker staining after bezafibrate treatment. (B) Quantification of myotubes with perinuclear MitoTracker-positive aggregates in untreated (vehicle) or bezafibrate-treated myotubes at DM-2. Data represent mean ± SD (*n* = 3). \*, P \< 0.001 by Student's *t* test. (C) MitoTracker (red) and LC3 immunostaining (green) of myotubes at DM-2. Chloroquine and 3-MA (where indicated) were added 12 h before staining. Note the extensive overlap of MitoTracker and LC3 in Rb^−/−^ myotubes (yellow), which is inhibited by 3-MA. (D) Mean percentage of MitoTracker (red) to LC3 (green) overlap in 25 myotubes from two independent cultures in control versus Rb^−/−^ myotubes (total) or Rb^−/−^ myotubes with perinuclear mitochondrial aggregation (high). \*, P = 7 × 10^−5^ by Student's *t* test. (E) Ultrastructural analysis of myotubes treated or not with 3-MA at DM-2. Arrowheads point to mitochondria. Asterisks indicate electron-dense autolysosomes. N, nucleus. (F) Ratio of mitochondrial DNA/nuclear DNA in the indicated cultures (*n* = 3). (G) Ratio of mitochondrial DNA/nuclear DNA in E16.5 skeletal muscle (*n* = 3; \*, P = 0.009). (H) Quantification of ATP in E16.5 skeletal muscle (*n* = 3; \*, P = 0.011). (F--H) Error bars represent SD. \*, P \< 0.001.](JCB_201005067_RGB_Fig2){#fig2}

Inhibition of autophagy rescues Rb differentiation defect
---------------------------------------------------------

The aforementioned results prompted us to ask whether inhibition of cell death or autophagy would rescue Rb^−/−^ myotube degeneration. Strikingly, adenovirus-mediated transduction of the survival factor Bcl-2, which inhibits both apoptosis and autophagy ([@bib39]), rescued the differentiation defect, leading to long multinucleated myotubes that expressed MHC and muscle creatine kinase (MCK), and twitched like control myotubes for \>3 wk in culture ([Fig. 3, A and B](#fig3){ref-type="fig"}; and [Videos 1](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1) and [2](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1)). Western blot analysis revealed that myogenin, MHC, MCK, and troponin T were undetectable in Rb^−/−^ cultures but expressed at comparable levels in Ad.Bcl-2--transduced Rb^−/−^ myotubes and control ([Fig. 3 C](#fig3){ref-type="fig"}).

![**Rescue of Rb-deficient myotube degeneration by Bcl-2 and autophagy inhibitors.** (A) Mean number of myotubes per field in indicated myoblast cultures induced to differentiate after transduction with Ad.GFP or Ad.Bcl-2. Each point represents the mean ± SD of six fields from six independent experiments. Bcl-2--rescued, twitching Rb^−/−^ myotubes are shown in [Video 2](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1). (inset) Western blot for Bcl-2 in Ad.Bcl2-transduced versus uninfected primary myoblasts. (B) Immunostaining for MCK (green) in Ad.Bcl-2--transduced control (ctrl) and Rb^−/−^ myotubes at DM-6. (C) Western blot for MCK, myogenin, MHC, and troponin T in indicated cultures at DM-6 after transduction with Ad.Bcl-2. Tubulin was used as a loading control. Black lines indicate that intervening lanes have been spliced out. (D) Mean number of Rb^−/−^ myotubes after 3-MA treatment, bezafibrate, or DMSO/vehicle as indicated. Counts are mean ± SD of six fields (*n* = 4). (E, left and middle) Brightfield images of the indicated myotubes treated or not with 3-MA at DM-8. (right) Immunostaining for MHC (red) at DM-14 in the presence of 3-MA. Arrowheads label 3-MA--rescued Rb^−/−^ myotubes at DM-8. 3-MA--rescued, twitching Rb^−/−^ myotubes are shown in [Video 4](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1). (F) Immunostaining for BrdU (green) and MHC (red) of 3-MA--treated cultures at DM-2 or DM-10. Rb^−/−^ myotubes incorporated BrdU at DM-2 (arrowheads) but not DM-10. (G) Brightfield images (left and middle) and MHC staining (right) of the indicated cultures treated or not with bezafibrate. Arrowheads point to bezafibrate-rescued Rb^−/−^ myotubes.](JCB_201005067_RGB_Fig3){#fig3}

Next, we treated cultures with 3-methyladenine (3-MA), an inhibitor of a class III phosphatidylinositol 3-kinase, Vps34, which is required for nucleation of the autophagic vesicle ([@bib26]). Remarkably, a single dose of 3-MA given just before the induction of differentiation prevented formation of LC3-positive perinuclear aggregates and perinuclear mitochondrial accumulation ([Fig. 2, C and D](#fig2){ref-type="fig"}, right) and blocked the degeneration of Rb^−/−^ myotubes, leading to myotubes that twitched for weeks in culture ([Fig. 3, D and E](#fig3){ref-type="fig"}; and [Videos 3](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1) and [4](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1)).

The number of myotubes formed was threefold lower after 3-MA treatment than after Bcl-2 transduction, but the extent of twitching was virtually the same (Videos 2 and 4). This is consistent with our observation that Bcl-2 expression increased survival of both myoblasts and myotubes, whereas 3-MA rescued myotube degeneration but increased apoptotic death of unfused myoblasts (unpublished data). Thus, different survival pathways operate in myoblasts and myotubes, and Rb^−/−^ myotube degeneration is cell autonomous, not an indirect consequence of high level of death in unfused cells. Adenoviral-mediated transduction of a dominant-negative Vps34 allele (Ad.Vps34^dn^; [@bib50]) also rescued the Rb myogenic defect, leading to twitching myotubes (Fig. S1 F). Collectively, these results indicate that degeneration of Rb^−/−^ myotubes is associated with autophagy of impaired mitochondria and that inhibition of this process rescues the Rb myogenic defect.

Rescued Rb^−/−^ myonuclei become stably postmitotic
---------------------------------------------------

In addition to increased autophagy, DM-2 Rb^−/−^ myotubes also exhibited ectopic DNA synthesis (Fig. S1 G; [@bib44]; [@bib8]). To determine the cell cycle status of 3-MA--rescued Rb^−/−^ myotubes, myoblasts were induced to differentiate in the presence or absence of 3-MA. After 1 or 9 d, the cultures were either maintained in DM or shifted to GM and treated with BrdU for 16 h. At DM-2, both 3-MA--treated and untreated Rb^−/−^ myotube nuclei but not control myotube nuclei labeled positive for BrdU ([Fig. 3 F](#fig3){ref-type="fig"}, left). Strikingly, by DM-10, 3-MA--treated Rb^−/−^ myotubes ceased to incorporate BrdU under either DM or GM conditions ([Fig. 3 F](#fig3){ref-type="fig"}, right). Thus, rescued Rb^−/−^ myotubes can eventually enter a stable postmitotic state.

In contrast to the effect of autophagy inhibitors, suppression of DNA synthesis with aphidicolin, or cell cycle progression with p27^kip1^, worsened the differentiation defect of Rb^−/−^ myoblasts ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1)). Transduction of activated mTOR ([@bib6]) or dominant-negative Foxo3a ([@bib46]), which inhibit autophagy induced by nutrient or insulin/IGF-1 deprivation ([@bib29]; [@bib58]), also failed to prevent Rb^−/−^ myotube degeneration, although both factors increased the number and size of control myotubes ([Fig. S3, A--D](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1)). Thus, Foxo3a and mTOR affect survival-associated autophagy in response to starvation but not death-associated autophagy that accompanies Rb^−/−^ myotube degeneration.

Peroxisome proliferator--activated receptor (PPAR) agonist and MOMP antagonist rescue the Rb differentiation defect
-------------------------------------------------------------------------------------------------------------------

If mitochondrial loss underlies myotube degeneration in the absence of pRb, we reasoned that stimulation of mitochondrial biogenesis might also rescue the defect. Mitochondrial biogenesis is regulated by the coactivator PGC-1α and PPARs, which can be activated by bezafibrate, a pan-PPAR agonist ([@bib3]; [@bib54]). As shown in [Fig. 3 (D and G)](#fig3){ref-type="fig"}, bezafibrate treatment efficiently blocked degeneration of Rb^−/−^ myotubes, leading to twitching myotubes that survived for \>8 d. Longer treatment with bezafibrate became cytotoxic to both control and Rb^−/−^ myotubes. Bezafibrate also increased overall mitochondrial content, observed by MitoTracker or cytochrome *c* staining ([Fig. 2 A](#fig2){ref-type="fig"}, right; and Fig. S1 H), and reduced the percentage of myotubes with perinuclear aggregates from ∼70 to 40% (P \< 0.001; [Fig. 2 B](#fig2){ref-type="fig"}). This result is in accord with a recent finding that during erythropoiesis, Rb deficiency disrupts mitochondrial biogenesis ([@bib43]). Next, we assessed the effect of blocking MOMP on Rb^−/−^ myotube survival using minocycline, an MOMP inhibitor ([@bib59]). Minocycline treatment delayed the collapse of mutant myotubes, which survived and twitched for 8 d (Fig. S3 E). In contrast, transduction of the x-linked inhibitor of apoptosis (XIAP), which inhibits multiple caspases ([@bib18]; [@bib25]), failed to block myotube degeneration (Fig. S3, F and G), indicating that collapse of Rb^−/−^ myotubes can only be effectively inhibited before MOMP.

Hypoxia-induced glycolytic shift rescues differentiation defect after chronic or acute inactivation of Rb
---------------------------------------------------------------------------------------------------------

The aforementioned results indicate that during differentiation, pRb loss leads to mitochondrial dysfunction and autophagy, reduced mitochondrial content and ATP levels, and ultimately myotube degeneration. An intriguing possibility is that a metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis would bypass the requirement for mitochondrial function and rescue the defect. To test this notion, we investigated the effect of hypoxia, which induces such a metabolic shift, on myogenic differentiation. A previous study showed that hypoxia inhibits the differentiation of immortalized satellite cells, C2C12 ([@bib13]). However, we found that differentiation of primary myoblasts was unaffected. Remarkably, Rb^−/−^ myotubes survived under hypoxic conditions (1% O~2~), leading to long MHC-expressing, twitching myotubes ([Fig. 4 A](#fig4){ref-type="fig"}). Immunoblotting confirmed high expression of both early (myogenin) and late (MCK) markers in hypoxia-rescued Rb^−/−^ myotube cultures ([Fig. 4 B](#fig4){ref-type="fig"}, left). Densitometry analysis of these factors, normalized for MHC expression (i.e., myotube number), revealed that although expression of MCK was near normal, expression of myogenin was elevated in rescued Rb^−/−^ myotubes relative to control, although this was not statistically significant ([Fig. 4 B](#fig4){ref-type="fig"}, right). When returned to normoxia after 5 d in hypoxia, rescued Rb^−/−^ myotubes continued to twitch, once again highlighting the transient requirement for Rb function in the first few days after differentiation.

![**Hypoxia rescues muscle degeneration after chronic or acute inactivation of Rb by inducing glycolysis via HIF-1α.** (A) Immunostaining for MHC (green) in the indicated myoblasts induced to differentiate under normoxia or hypoxia treated or not with lonidamine. Note the shortened myotubes in the presence of lonidamine. (B) Representative immunoblot (left) and mean expression of myogenin and MCK normalized for MHC expression (right; *n* = 3). (C) Rb^f/f^ myoblasts transduced with Ad.GFP or Ad.Cre and immunoblotted for pRb. Tubulin was used as a loading control. (D) Rb^f/f^ myoblasts transduced with Ad.GFP or Ad.Cre and immunostained for pRb (red). (insets) DAPI staining for nuclei (blue). (E) Immunostaining for MHC in Rb^f/f^ myoblasts transduced with Ad.Cre and induced to differentiate in normoxia (top and middle) or hypoxia (bottom). (F, top) Brightfield images of Rb^f/f^ myoblasts transduced with Ad.EV or Ad.Cre and induced to differentiate under hypoxia. (bottom) Larger view of the boxed field. Arrowheads point to rescued Rb^−/−^ myotubes. This field is shown in [Video 6](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1). (G) Quantification of myotube formation in Rb^f/f^ myoblasts transduced with Ad.EV or Ad.Cre and induced to differentiate under hypoxia. Counts are mean of six representative fields (*n* = 3). \*, P = 0.004. (H) Quantification of myotube formation in the indicated myoblasts induced to differentiate under the indicated conditions. Myotube counts are the mean of six fields (*n* = 4). (I) MHC staining (red) of the indicated myoblasts transduced with Ad.NF-κB/HIF-1α and induced to differentiate in normoxia. (J) Quantification of myotube formation in the indicated myoblasts transduced with Ad.EV or Ad.NF-κB/HIF-1α and induced to differentiate in normoxia. Myotube counts are the mean of six fields (*n* = 3). Error bars represent SD.](JCB_201005067_RGB_Fig4){#fig4}

To test whether hypoxia could also rescue the Rb myogenic defect after acute inactivation of this tumor suppressor, we infected embryonic myoblasts from E16.5 Rb^f/f^ embryos in which exon 19 of Rb is flanked by loxP sites with adenovirus encoding Cre recombinase ([@bib53]; [@bib19]). We used high multiplicity of infection that deleted Rb^f/f^ in virtually all cells ([Fig. 4, C and D](#fig4){ref-type="fig"}). Remarkably, like after chronic inactivation, hypoxia rescued the differentiation defect after acute inactivation of Rb, leading to long, twitching myotubes that continued to contract even when transferred back to normoxia ([Fig. 4, E and F](#fig4){ref-type="fig"}; and [Videos 5](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1) and [6](http://www.jcb.org/cgi/content/full/jcb.201005067/DC1)).

Hypoxia-rescued Rb differentiation defect is glycolysis and hypoxia-inducible factor-1α (HIF-1α) dependent
----------------------------------------------------------------------------------------------------------

Under low oxygen tension, HIF-1α induces expression of genes responsible for glucose influx and glycolysis ([@bib31]). To determine whether hypoxia rescued Rb^−/−^ myotubes by inducing a glycolytic shift, myoblasts were induced to differentiate in hypoxia in the presence of lonidamine, an antagonist of hexokinase, which catalyzes the conversion of glucose to glucose 6-phosphate ([@bib40]). Beginning at DM-2, a relatively low concentration of 50 µM lonidamine had little obvious effect on the survival of control myotubes in hypoxia ([Fig. 4, A and G](#fig4){ref-type="fig"}). In contrast, under hypoxia, mutant myoblasts were highly sensitive to this dose of lonidamine, forming only very short myotubes, most of which ultimately degenerated ([Fig. 4, A and G](#fig4){ref-type="fig"}).

Under normoxia, HIF-1α undergoes ubiquitination via the von Hippel--Lindau tumor suppressor protein (VHL), leading to its proteosomal degradation ([@bib31]). To ask whether HIF-1α was responsible for preventing the degeneration of Rb^−/−^ myotubes in hypoxia, we first used a VHL allele that is constitutively active both in normoxia and hypoxia (Ad.VHL-T7-HPACGV; [@bib47]). Expression of this allele dramatically reduced survival of Rb^−/−^ myotubes under hypoxic conditions ([Fig. 4 G](#fig4){ref-type="fig"}, bottom right), implicating HIF-1α in mediating rescue of Rb^−/−^ myotubes under low oxygen tension. Next, we tested whether HIF-1α was sufficient to prevent Rb^−/−^ myotube degeneration using a constitutively active HIF-1α allele, HIF-1α/NF-κB, where the N terminus of HIF-1α is fused to the NF-κB transactivation domain ([@bib52]). Transduction of Ad.HIF-1α/NF-κB rescued degeneration of Rb^−/−^ myotubes in normoxia, leading to stable myotubes for \>10 d ([Fig. 4, H and I](#fig4){ref-type="fig"}). We conclude that Rb^−/−^ myotubes survive in hypoxia because of an HIF-1α--induced glycolytic shift.

Our results demonstrate that pRb is required for survival during terminal myogenesis but not to actively stimulate the myogenic differentiation program. Although we do not rule out the possibility that interaction of pRb with MyoD may be involved in cell cycle exit or survival, the presence of pRb is clearly not required for myoblast differentiation in vitro. Our results are consistent with observations that Rb^−/−^ cells can efficiently contribute to most adult tissues in Rb^−/−^:Rb^+/+^ chimeric mice ([@bib27]; [@bib55]; [@bib49]). In muscle, Rb^+/+^ cells can complement the Rb^−/−^ defect after cell fusion. However, in other tissues, it appears that most Rb^−/−^ cells are inherently capable of functional differentiation. This has direct implications for differentiation-induced therapy for Rb mutant cancer cells.

We show that pRb is required during myogenesis to suppress mitochondrial destruction. In most Rb^−/−^ cell types, including unfused myoblasts, induction of differentiation at low mitogens leads to MOMP and apoptotic cell death. In Rb^−/−^ myotubes, we suggest that the intrinsic apoptotic machinery is inactive and that mitochondrial dysfunction leads to disruption of the mitochondrial network, perinuclear aggregation, and autophagic degradation. A similar interplay between inhibition of caspase-dependent apoptosis and autophagy has been documented in other contexts ([@bib56]; [@bib45]). We propose that abortive cell differentiation in Rb^−/−^ cells is caused by mitochondrial dysfunction and survival factors that can restore mitochondrial function or redirect metabolism toward glycolysis can maintain Rb^−/−^ cell survival and differentiation.

A switch from OXPHOS to glycolysis ([@bib11]; [@bib51]) and Rb inactivation ([@bib7]; [@bib5]) represents two major hallmarks of cancer. Our results indicate that Rb loss leads to inappropriate cell division, which is oncogenic, and also to impaired mitochondrial function, which promotes cell death. Therefore, in the context of neoplastic transformation, Rb loss must cooperate with mutations that effectively suppress mitochondrial damage or autophagy or shift ATP production from OXPHOS to glycolysis. Some of the latter mutations may directly induce glycolysis, whereas others may cooperate with deregulated E2F to transcriptionally activate glycolytic genes ([@bib12]). Thus, we have identified a novel role for pRb in maintaining mitochondrial integrity that is important for normal differentiation and has implications for cancer metabolism.

Materials and methods
=====================

Mouse analysis
--------------

Experiments were performed in accordance with guidelines of the Canadian Council on Animal Care and Animal Ethics Committee (University Health Network, Toronto, Ontario, Canada). Mice were genotyped using DNA extracted from tail biopsies and the following primers: mgRb/Rblox (forward), 5′-ATTTCAGAAGGTCTGCCAAC-3′ and (reverse) 5′-AGAGCAGGCCAAAAGCCAGGA-3′; Rb mutant (forward), 5′-AATTGCGGCCGCATCTGCATCTTTATCGC-3′ and (reverse) 5′-GAAGAACGAGATCAGCAG-3′; Rb wild type (forward), 5′-AATTGCGGCCGCATCTGCATCTTTATCGC-3′ and (reverse) 5′-CCCATGTTCGGTCCCTAG-3′; Rb^floxed^ (Rb18 + Rb19E) (forward), 5′-GGCGTGTGCCATCAATG-3′ and (reverse) 5′-CTCAAGAGCTCAGACTCATGG-3′. For timed pregnancies, mice were mated overnight, and the day of vaginal plug observation was considered E0.5.

Primary myoblast cell cultures
------------------------------

Over 1,000 embryos from \>200 timed pregnancies were used in this study to generate primary mouse embryonic myoblast cultures. To maintain consistency between experiments, primary myoblasts were induced to differentiate at passage 2. Myoblasts were isolated from skeletal muscle of limbs of E.16.5--17.5 embryos. Tissues were digested for 20 min at 37°C in 80 µl solution containing 1.5 U/ml collagenase IV (Sigma-Aldrich), 2.4 U/ml dispase (Roche), and 5 mM CaCl~2~ gently triturated and plated onto a 60-mm collagen I--coated culture dish. Myoblasts were maintained in growth medium (GM), HAM's-F10 (Lonza) supplemented with 20% FBS (PAA), and 2.5 ng/ml basic FGF (Sigma-Aldrich), in a humidified incubator at 5% CO~2~ and 37°C. To induce differentiation, myoblasts were rinsed once in 1× PBS and shifted to DM, DME, high glucose, and sodium pyruvate (Sigma-Aldrich), supplemented with 3% horse serum (PAA; [@bib17]). Adenoviruses were amplified in 293T cells maintained in DME plus 10% FBS and penicillin/streptomycin (Sigma-Aldrich). For drug treatment, a single dose of 5 mM 3-MA was added upon differentiation. 500 µM bezafibrate and 200 µM minocycline were refreshed every other day. 40 µM chloroquine was added for 12 h before harvesting the cells. Aphidicolin was used at 2.5 µg/ml. For hypoxia experiments, confluent myoblast cultures were fed DM and transferred hypoxic conditions (1% O~2~). 50 µM lonidamine (refreshed every other day; Sigma-Aldrich) and Ad.VHL-T7-HPACGV were added at DM-1.

BrdU DNA synthesis assay
------------------------

DM-1 myotube cultures were restimulated in GM or maintained in DM supplemented with 20 µM BrdU for 16 h before fixation with 3.7% formaldehyde (10 min). Aphidicolin was added 5 h before addition of BrdU for 16 h. Cultures were permeabilized using 0.3% Triton X-100 for 10 min, treated with 2 N HCl for 25 min, and neutralized with two washes of 0.5 M sodium borate, pH 8.5, for 5 min. After blocking in 1.0% BSA for 20 min and anti-MHC antibody (1:50; Sigma-Aldrich) for 1 h, cells were washed three times for 3 min each with PBS. Secondary antibody fluorescein-conjugated Alexa Fluor 563 (red; Invitrogen) was used. BrdU was detected using anti-BrdU antibody conjugated to FITC (Alexa Fluor 488) and diluted as per manufacturer's protocol (BD). Confocal images of 0.5-µm sections were captured at room temperature using a 40× or 63× 1.2 NA C Apochromat water objective lens using a confocal microscope (LSM510 META; Carl Zeiss, Inc.) and acquisition software (AIM 3.2; Carl Zeiss, Inc.). Photoshop (CS2; Adobe) was used to overlay images.

Immunofluorescence and EM
-------------------------

500,000 myoblasts were seeded on 22-mm round collagen I--coated coverslips (BD) and induced to differentiate. Cells were fixed in 3.7% formaldehyde, permeabilized in 0.3% Triton X-100, and blocked for 20 min in 1% BSA/PBS at room temperature. The following antibodies and dilutions were used: myogenin, 1:10 (F5D; Santa Cruz Biotechnology, Inc.); MHC, 1:50 (Sigma-Aldrich); MCK, 1:50 (Santa Cruz Biotechnology, Inc.), cytochrome *c*, 1:50 (clone A-8; Santa Cruz Biotechnology, Inc.). Secondary antibodies fluorescein-conjugated Alexa Fluor 563 and 488 (Invitrogen) were added for 45 min. Nuclei were counterstained with DAPI (Invitrogen) for 10 min and mounted in fluorescent mounting media (Dako). Mitochondrial LC3 (red/green) colocalization was conducted with the Colocalization plug-in for ImageJ (National Institutes of Health). Electron micrographs were captured at 80 kV using a transmission electron microscope (H-7000; Hitachi) equipped with an AMT digital camera (Hitachi) at the University of Toronto. Image contrast was enhanced using Photoshop.

Western blot analysis
---------------------

Cells were lysed on ice in K4IP buffer (50 mM Hepes, pH 7.5, 0.1% Tween-20, 1 mM EDTA, 2.5 mM EGTA, 150 mM NaCl, 1.0 mM DTT, and 10% glycerol) containing protease inhibitors (Sigma-Aldrich). The following antibodies and dilutions were used for 3 h at room temperature or overnight at 4°C: α/β-tubulin, 1:4,000 (Cell Signaling Technology); MHC, 1:200 (Sigma-Aldrich); LC3b, 1:500 (Cell Signaling Technology); MCK, 1:200 (Santa Cruz Biotechnology, Inc.); pRb, 1:1,000 (BD); troponin T-FS, 1:200 (clone c-18; Santa Cruz Biotechnology, Inc.); poly(ADP-ribose) polymerase, 1:500 (Cell Signaling Technology); and caspase-3, 1:500 (Cell Signaling Technology). Secondary antibodies used were HRP-linked anti-IgG at 1:2,000 (Cell Signaling Technology) for 1.5 h in blocking buffer, and HRP activity was detected using SuperSignal West Dura chemiluminescent substrate (Thermo Fisher Scientific) and captured by x-ray film. Films were digitized using a scanner (Canon). Quantification of Western blots was conducted using Photoshop.

Mitochondrial and nuclear DNA quantitative PCR
----------------------------------------------

Mitochondrial DNA copy number was quantified for an 80-bp fragment of mouse mitochondrial DNA (primers: forward, 5′-GCAAATCCATATTCATCCTTCTCAAC-3′; reverse, 5′-GAGAGATTTTATGGGTGTAATGCGGTG-3′) relative to the NADH dehydrogenase (ubiquinone) flavoprotein 1 single-copy nuclear gene (GenBank/EMBL/DDBJ accession no. NM_133666) (primers: forward, 5′-CTTCCCCACTGGCCTCAAG-3′; reverse, 5′-CCAAAACCCAGTGATCCAGC-3′) using quantitative real-time PCR (7900T lightcycler; Applied Biosystems).

ATP, MitoTracker red CMXRos, and TUNEL assays
---------------------------------------------

ATP quantification was performed using a luminescence detection system according to the manufacturer's protocol (ATPlite; PerkinElmer). Mitochondria membrane potential was detected using MitoTracker red CMXRos according to the manufacturer's protocol (Molecular Probes). For TUNEL, differentiating myoblasts on collagen I--coated coverslips were fixed in 3.7% formaldehyde for 10 min, washed three times in PBS, permeabilized with 0.3% Triton X-100 solution, and washed three times in PBS. Subsequently, 30 U TdT (Fermentas) was added to 50 µl TUNEL label solution (Roche).

Adenovirus Cre infections
-------------------------

For adenovirus Cre (Ad.cre; Vector Biolabs) infection of Rb^f/f^ myoblasts, cells were transduced at a multiplicity of infection of 1,300. At a lower multiplicity of infection (\<1,000), some pRb-positive nuclei within myotubes were still detected. 48 h after transduction, myoblasts were induced to differentiate. For all other recombinant adenoviruses, transduction was performed when cultures were induced to differentiate. The following adenovirus vectors were provided by the indicated sources: Ad.Bcl-2 (M. Crescenzi, Higher Institute of Health, Rome, Italy), Ad.GFP-LC3 and Ad.RFP-LC3 (A.M. Tolkovsky, University of Cambridge, Cambridge, England, UK), Ad.HIF-1α/NF-κB and Ad.EV (K.A. Vincent, Genzyme Corporation, Framingham, MA), Ad.VHL-T7-HPACGV (M. Ohh, University of Toronto, Toronto, Ontario, Canada), Ad.Vps34^DN^ (D. Murphy, University of Bristol, Bristol, England, UK), Ad.mTOR, Ad.KD.mTOR, and Ad.ca.mTOR (C.J. Rhodes, The University of Chicago, Chicago, IL), Ad.FOXO3a and Ad.DN.FOXO3a (K. Walsh, Boston University School of Medicine, Boston, MA), Ad.Rb^ΔK11^ and Ad.p27 (D.S. Park, University of Ottawa, Ottawa, Ontario, Canada), and Ad.XIAP and anti-XIAP antibody (R.G. Korneluk, University of Ottawa, Ottawa, Ontario, Canada).

Brightfield images and videos
-----------------------------

Brightfield images and videos were captured at room temperature using 20× or 40× air objective lenses on a microscope (TE200; Nikon) fitted with a charge-coupled device digital camera (Hamamatsu Photonics). Images were acquired using imaging software (SimplePCI; Hamamatsu Photonics). Photoshop was used to enhance clarity and contrast using same parameters for control and experimental samples.

Online supplemental material
----------------------------

Fig. S1 shows characterization of myogenic defects during abortive differentiation of Rb^−/−^ myoblasts. Fig. S2 shows that cell cycle inhibitors aphidicolin and p27^Kip1^ accelerate the degeneration of Rb^−/−^ myotubes. Fig. S3 shows differential effects of mTOR, Foxo3, minocycline, and XIAP on differentiation of Rb^−/−^ myoblasts. Video 1 shows twitching control myotubes (Ad.Bcl-2 transduced), Video 2 shows twitching Rb^−/−^ myotubes (Ad.Bcl-2 transduced), Video 3 shows twitching control myotubes (3-MA treated), Video 4 shows twitching Rb^−/−^ myotubes (3-MA treated), Video 5 shows twitching control Ad.EV-transduced Rb^f/f^ myotubes (hypoxia), and Video 6 shows twitching Rb^Δf^ myotubes (hypoxia). Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201005067/DC1>.
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